Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 2948-2956

  Chan, Kevin E ^a,b   Lafayette, Richard A ^a   Whittemore, Alice S ^b   Hlatky, Mark A ^b   Moran, John ^c  

^a Division of Nephrology   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Minnesota   (United States)

Author keywords

Anemia management; ESRD; Processes of care

Indexed keywords

HEMOGLOBIN; PARATHYROID HORMONE;

ADULT; AGED; ANEMIA; ARTICLE; GENDER; HEALTH CARE FACILITY; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANEMIA; C-REACTIVE PROTEIN; EPOETIN ALFA; HEALTH FACILITIES; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; LOGISTIC MODELS; ODDS RATIO; ORGANIZATIONS, NONPROFIT; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 57049100877     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn172     Document Type: Article

References (33)

1. Adamson JW. Anemia of end-stage renal disease. Kidney Int 1985; 28: 1-5
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
3. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
4. Collins AJ, Brenner RM, Ofman JJ et al. Epoetin alfa use in patients with ESRD. An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-488
5. National Kidney Foundation NKF-K/DOQI. Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1): S182-S238
6. Macdougall IC, Coles GA, Williams JD et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493
7. Evans RW, Rader B, Manninen DL. Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 63: 825-820
8. Ofsthun N, Labrecque J, Lacson E. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914
9. Lowrie EG, Huang WH, Lew NL et al. The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA (ed.) Death on Hemodialysis. Preventable or Inevitable? Boston, MA: Kluwer, 1994, 121-141
10. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
11. Phrommintikul A, Haas SJ, Maros, E et al. Mortality and target hemoglobin concentration in anemic patients with chronic kidney disease treated with erythropoietin: a meta analysis. Lancet 2007; 369: 381-388
12. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
13. Fink JC, Hsu VD, Zhan M et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653
14. Bems J, Elzein H, Lynn R et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
15. Improving the quality of care for beneficiaries with end-stage renal disease. The Medicare Payment Advisory Commission, 1999. Available at http://www.medpac.gov/publications/congressional-reports/Jun99%20Ch8.pdf
16. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124
17. Messana T. Erythropoietin claims monitoring policy. Implications for clinical practice. Nephrol Nurs J 2006; 33: 209-222
18. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
19. NKF-K/DOQI. Clinical practice guidelines for anemia of chronic disease: update 2000 (www.kidney.org/professionals/kdoqi/guidelinesupdates/doqi uptoc.html)
20. NKF-DOQI. Clinical practice guidelines for anemia of chronic renal failure: IV. Administration of epoetin. Am J Kidney Dis 2001; 37(Suppl 1): S207
21. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 1999; 33: 63-71
22. Berns J, Elzein H, Lynn R et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
23. National Kidney Foundation. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
24. National Kidney Foundation. K/DOQI. Clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S1-S266
25. Drueker T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(Suppl 7): 25-28
26. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-71
27. Kalantar-Zadeh K, Kopple JD, Block G et al. A malnutrition- inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263
28. Yeun JY, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
29. Fink JC, Hsu VD, Zhan M et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653
30. Kaysen GA, Muller HG, Ding J et al. Challenging the validity of EPO index. Am J Kidney Dis 2006; 47: 166
31. Brimble KS, Rabbat CG, McKenna P et al. Protocolized anemia management with erythropoietin in hemodialysis patients. A randomized controlled trial. J Am Soc Nephrol 2003; 14: 2654-2661
32. Coladonato JA, Frankenfield DL, Reddan DN et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-1295
33. Reddan DN, Frankenfield DL, Klassen PS et al. Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant 2003; 18: 147-152